Stoke Therapeutics (STOK) News Today $11.68 +0.38 (+3.36%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy RecommendationDecember 20 at 2:52 PM | msn.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Here's What HappenedStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Time to Sell?December 20 at 11:44 AM | marketbeat.comChardan Capital Initiates Coverage on Stoke Therapeutics (NASDAQ:STOK)Chardan Capital began coverage on shares of Stoke Therapeutics in a report on Friday. They set a "buy" rating and a $24.00 price objective for the company.December 20 at 8:31 AM | marketbeat.comJane Street Group LLC Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)Jane Street Group LLC boosted its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 338.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330,442 shares of the company's stock after buying an additionDecember 19 at 3:51 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Stock Price Down 5% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Shares Down 5% - Here's WhyDecember 18 at 2:20 PM | marketbeat.comCompanies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In GrowthDecember 17, 2024 | uk.finance.yahoo.comBrokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $20.83December 15, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Fmr LLCFmr LLC trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 18.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 322,949 shares of the company's stock after selling 75,070 shares durinDecember 14, 2024 | marketbeat.comStoke Space hotfires rocket engine on new vertical test stand — a ‘very big deal’ for Washington startupDecember 13, 2024 | msn.comStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 2,586 SharesDecember 12, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Buy" from AnalystsShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have been assigned a consensus rating of "Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buyDecember 12, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) CEO Sells $78,852.60 in StockDecember 11, 2024 | insidertrades.comStoke Therapeutics (NASDAQ:STOK) Receives "Overweight" Rating from Cantor FitzgeraldDecember 11, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Bought by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 1,589.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,154 shares of the company'December 11, 2024 | marketbeat.comStoke Therapeutics: Promising Developments in Seizure Treatment Bolster Buy RatingDecember 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Silence Therapeutics (SLN)December 10, 2024 | markets.businessinsider.comStoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet SyndromeDecember 6, 2024 | businesswire.comPreveCeutical Medical Inc.: BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry TichoDecember 5, 2024 | finanznachrichten.deStoke Therapeutics (NASDAQ:STOK) Stock Quotes, Forecast and News SummaryDecember 5, 2024 | benzinga.comBioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry TichoDecember 5, 2024 | finance.yahoo.comRTW Investments LP Buys 427,447 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)RTW Investments LP raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,652,285 shares of the company's stock after acquiring an additional 427,447 sharDecember 5, 2024 | marketbeat.comStoke Therapeutics Shares Rise Premarket on Key FDA DesignationDecember 5, 2024 | marketwatch.comStoke Therapeutics Receives Breakthrough Therapy Designation For ZorevunersenDecember 5, 2024 | markets.businessinsider.comStoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeDecember 5, 2024 | finance.yahoo.comBarry Ticho Sells 10,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) StockDecember 4, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Buy" by BrokeragesStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and oNovember 17, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 8.3% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Trading Down 8.3% - What's Next?November 15, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases 36,240 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Los Angeles Capital Management LLC boosted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 54.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,005 shares of the company's stock afteNovember 15, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for STOK FY2024 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share estimates for Stoke Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($2.00November 8, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for STOK EarningsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earningsNovember 8, 2024 | marketbeat.comWedbush Lifts Earnings Estimates for Stoke TherapeuticsStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at Wedbush upped their FY2024 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, November 5th. Wedbush analyst L. Chico now forecasts that the company will earnNovember 8, 2024 | marketbeat.comOptimistic Buy Rating for Stoke Therapeutics: Strategic Focus on Zorevunersen and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comStoke Therapeutics’ Zorevunersen Shows Promising Efficacy in Reducing Seizures and Improving Quality of Life, Justifying Buy RatingNovember 6, 2024 | markets.businessinsider.comStoke Therapeutics Reports Q3 Results, Focuses on Phase 3 StudyNovember 6, 2024 | markets.businessinsider.comNeed To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) RevenuesNovember 6, 2024 | finance.yahoo.comStoke Therapeutics’ Promising Outlook: Buy Rating Backed by Positive Study Results and Strategic AdvancementsNovember 6, 2024 | markets.businessinsider.comStoke Therapeutics: Promising Growth Potential Backed by Strategic Advancements and Financial StabilityNovember 6, 2024 | markets.businessinsider.comStoke Therapeutics (NASDAQ:STOK) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday.November 6, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday.November 6, 2024 | marketbeat.comStoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesNovember 6, 2024 | finanznachrichten.deStoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.1% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Trading Down 4.1% - Time to Sell?November 5, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. reduced its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,312,479 shares of the company's stock after selling 155,723 shares during the perioOctober 27, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) is Skorpios Trust's Largest PositionSkorpios Trust lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 17.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,906,181 shares of the company's stock after selling 1,937,500 shaOctober 26, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 78.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 14,917 shares of the company's stock after selling 53,684 shares during the quarOctober 24, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by BrokeragesShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received a consensus rating of "Buy" from the nine research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommeOctober 23, 2024 | marketbeat.comQ4 EPS Forecast for Stoke Therapeutics Raised by AnalystStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Leerink Partnrs boosted their Q4 2024 earnings per share estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects thatOctober 18, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Upgraded to "Strong-Buy" by Leerink PartnrsLeerink Partnrs raised Stoke Therapeutics to a "strong-buy" rating in a research report on Friday.October 15, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up - Here's WhyStoke Therapeutics (NASDAQ:STOK) Shares Gap Up - Here's WhyOctober 14, 2024 | marketbeat.comLeerink Partners Begins Coverage on Stoke Therapeutics (NASDAQ:STOK)Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday. They issued an "outperform" rating and a $18.00 price objective on the stock.October 14, 2024 | marketbeat.comMillennium Management LLC Buys 243,083 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Millennium Management LLC raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 528.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 289,067 shares of the company's stock after purchasing anOctober 14, 2024 | marketbeat.com Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin STOK Media Mentions By Week STOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.840.60▲Average Medical News Sentiment STOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼87▲STOK Articles Average Week Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HCM News CPRX News AGIO News PTGX News IOVA News AMRX News LBPH News NAMS News IDYA News CNTA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts